Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Thomas Powles comments on practice changing results in the management of urothelial cancer and new biomarker data for improved patients selection.
He first talks about the effect on the risk of death of starting maintenance immunotherapy right after chemotherapy in patients with advanced urothelial cancer, that was demonstrated in the JAVELIN 100 trial. These practice changing results in the front line setting were validated in broad subgroups of patients.
Secondly he discusses the interesting results from the DUTRENEO study, evaluating pathologic complete response to immunotherapy combination vs chemotherapy in patients with muscle-invasive urothelial bladder cancer, selected according to interferon-gamma immune signature.
Finally he looks in the results from the exploratory analysis of biomarkers data from the IMvigor130 trial testing the Immunotherapy vs immunotherapy combination with chemotherapy vs chemotherapy alone in metastatic urothelial cancer. He focuses on the promising results presented in the PD-L1, TMB and combined biomarkers subgroups of patients.
Abstracts:
- LBA1: Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis - Thomas Powles
- 5012: DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature - Enrique Grande
- 5011: Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study – Matthew Galsky
This video is part of the Genitourinary Cancers track 2020, supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.